Startups
Edit
Cilag GmbH International (former Covagen AG)
https://covagen.com/?refid=242Last activity: 17.04.2015
Probably Closed
Covagen is a privately held company pioneering the commercialization of Fynomers as next generation protein drugs to address unmet medical needs in inflammatory diseases and cancer. Fynomers represent a novel class of protein therapeutics. Due to their favorable biophysical properties, Fynomers with different binding specificities can be combined in a single molecule, thus creating drugs with new mechanisms of action.
Overview
Total raised
$72.14M
Investors 3
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Andera Partners | anderapartners.com | |
| GIMV | gimv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Dec 10, 2013 | Series B round | $63M | |
| Dec 2, 2010 | Series A round | $6.33M |
Mentions in press and media 16
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 25, 2014 | Janssen Affiliate Cilag GmbH International Acquires Covagen AG | |
| May 5, 2014 | Covagen’s first clinical trials | |
| Mar 24, 2014 | Red Herring Europe: 15 Swiss Finalists | |
| Feb 20, 2014 | Covagen Raises Additional CHF2.5M in Series B Round | Covagen, a Swiss preclinical-stage biotech company, raised an additional CHF2.5m in funding. Baxter Ventures joined as an investor in a Series B financing round, which now amounts to CHF44.9m (read about the CHF42m recent close here). The S... |
| Feb 19, 2014 | Covagen Adds Baxter Ventures as Investor | |
| Dec 10, 2013 | Covagen secures CHF 42 Million in Series B Financing | Covagen secures CHF 42 Million in Series B Financing 10.12.2013 11:00, Mélanie Mojon linkedIn facebook twitter instagram youtube --> Covagen, venture leaders alumni, announced that the company has secured CHF 42 million in a tranched Ser... |
| Dec 10, 2013 | Covagen Secures CHF42M in Series B Financing | Covagen, a Swiss preclinical-stage biotech company, secured CHF42m in Series B financing. The round was led by new investor Gimv (with CHF 8.3m) with participation of new investor Ascent Biomedical Ventures and existing investors Novartis V... |
| Dec 10, 2013 | Covagen Secures CHF 42 Million in Series B | ZURICH-SCHLIEREN, SWITZERLAND, Covagen today announced that the company has secured CHF 42 million in a tranched Series B financing. >> Click here for more funding data on Covagen >> To export Covagen funding data to PDF and... |
| Dec 9, 2013 | Covagen gets up to $63M in VC round for multitargeted antibodies | Researchers at Swiss biotech startup Covagen are in the business of building multitargeted antibodies, new bi- and trispecific therapies which are created by fusing short proteins onto the arms and tail of the Y-shaped body of the original ... |
Show more
Reviews 0
FAQ about Cilag GmbH International (former Covagen AG)
How much funding has Cilag GmbH International (former Covagen AG) raised?
Cilag GmbH International (former Covagen AG) has raised $72.14M in total across 3 funding rounds.
What funding rounds has Cilag GmbH International (former Covagen AG) raised?
Parsers VC lists 3 funding rounds of Cilag GmbH International (former Covagen AG), among them a Series B round of $63M on Dec 10, 2013 and a Series A round of $6.33M on Dec 2, 2010.
Who has invested in Cilag GmbH International (former Covagen AG)?
Parsers VC lists 3 investors of Cilag GmbH International (former Covagen AG), among them Andera Partners and GIMV.
What has the press written about Cilag GmbH International (former Covagen AG)?
Parsers VC has collected 16 articles mentioning Cilag GmbH International (former Covagen AG), among them “Janssen Affiliate Cilag GmbH International Acquires Covagen AG” (Aug 25, 2014) and “Covagen’s first clinical trials” (May 5, 2014).
Is Cilag GmbH International (former Covagen AG) still active?
Cilag GmbH International (former Covagen AG) is probably closed: its latest activity on Parsers VC dates from Apr 17, 2015.